Barrington analyst Michael Petusky lowered the firm’s price target on Haemonetics (HAE) to $95 from $108 and keeps an Outperform rating on the shares post the fiscal Q3 report. The firm cites reduced growth expectations for the hospital segment for the target cut. However, Haemonetics delivered a 25.7% adjusted operating margin in the quarter, another data point suggesting that the company can achieve its target of upper 20%s adjusted operating margins by fiscal 2026, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics downgraded to Underperform from Neutral at BofA
- Haemonetics price target lowered to $100 from $125 at JMP Securities
- Haemonetics Reports Strong Q3 Financial Results
- Haemonetics narrows FY25 adjusted EPS view to $4.50-$4.70 from $4.45-$4.75
- Haemonetics reports Q3 adjusted EPS $1.19, consensus $1.17